Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dana-Farber Cancer Institute, Boston
Steroid hormone receptor status is suggested as predictor for response to adjuvant therapy
February 5th, 2006
Steroid hormone receptor status is suggested as a predictor for measuring response to adjuvant therapy. "Therapeutic effects of adjuvant therapies for breast cancer have been assessed 'across the board' and implemented using the principle that if a treatment is effective 'on average' then it is effective 'for all patients,'" stated scientists in the United States. "Exploration and improved understanding of the biological basis for predicting response to available adjuvant therapies is essential to enhance patient care. As illustration, we consider the effects of chemotherapy and tamoxifen in two International Breast Cancer Study Group (IBCSG) trials for postmenopausal...
Source: Women's Health Law Weekly (2006-02-05)
|
